Starry(SH:603520)2025-04-29 15:23Financial Performance - The company's operating revenue for 2024 reached ¥2,350,224,699.38, representing a 7.02% increase compared to ¥2,195,986,154.85 in 2023[26] - The net profit attributable to shareholders of the listed company was -¥49,098,979.53, a decrease of 211.00% from ¥44,232,089.55 in the previous year[26] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥54,129,914.26, down 251.56% from ¥35,714,402.86 in 2023[26] - The net cash flow from operating activities increased significantly to ¥193,502,193.81, a 334.33% rise from ¥44,552,117.23 in the previous year[26] - The total assets of the company at the end of 2024 were ¥6,045,615,210.30, reflecting a 9.59% increase from ¥5,516,420,403.90 at the end of 2023[26] - The net assets attributable to shareholders of the listed company increased to ¥2,628,155,919.06, a 49.96% increase from ¥1,752,604,843.99 in 2023[26] - The basic earnings per share decreased to -0.12 yuan, down 192.31% from the previous year[28] - The weighted average return on equity fell to -2.16%, a decrease of 4.69 percentage points year-on-year[28] Business Operations - The company continued to expand its formulation business, with the fifth batch of centralized procurement products, iodinated contrast agent, progressing well, having completed bidding in 28 provinces by February 2025[40] - The company is focusing on the integration of intermediates, APIs, and formulations while enhancing its international sales layout[40] - The company's domestic formulation business achieved sales revenue of CNY 558 million, a year-on-year increase of 13.75%[41] - International sales of contrast agent raw materials grew rapidly, with a year-on-year increase of 21%[41] - The company's formulation business in Ireland reported sales revenue of CNY 86.203 million, a year-on-year increase of 60%[41] - The company aims to achieve over 40% of its revenue from overseas business in 2024, with end customers across more than 30 countries on five continents[41] Research and Development - R&D expenses totaled ¥140,672,339.26, representing 6.07% of total revenue, with capitalized R&D accounting for 1.45%[70] - The company employed 390 R&D personnel, representing 22% of the total workforce[71] - The company has established multiple R&D bases across Zhejiang, Jiangxi, and Shanghai, equipped with modern laboratories for various research purposes[89] - The company is actively involved in the development of non-ionic iodine contrast agents and gadolinium-based agents[89] - The company achieved a research and development investment of 12,752.69 million RMB for API, representing 5.43% of operating revenue, with a year-on-year increase of 17.72%[103] Environmental Responsibility - The company invested 11,202.68 million CNY in environmental protection during the reporting period[163] - The company achieved a total wastewater discharge of 534,235 tons in 2024, with COD emissions of 170.32 tons and ammonia nitrogen emissions of 3.48 tons[164] - The company has committed to reducing carbon emissions through advanced production processes and the establishment of a photovoltaic power station[185] - The company has established a comprehensive self-monitoring plan for environmental compliance, which is publicly available on the Zhejiang Province self-monitoring information platform[181] - The company has improved its ability to treat high-concentration COD and high-salinity wastewater through technological upgrades[183] Corporate Governance - The company held three shareholder meetings during the reporting period, all in compliance with relevant laws and regulations[124] - The company has independent directors serving on multiple boards, enhancing governance and oversight[129] - The remuneration decision process for directors and senior management is governed by the company's compensation management policy[130] - The company has implemented a performance evaluation system to determine actual remuneration for its directors and senior management[130] - The company has not faced significant changes in competition from controlling shareholders or related parties[124] Future Outlook - The company provided guidance for 2024, expecting revenue to grow by 12% to approximately $1.68 billion[136] - New product launches are anticipated to contribute an additional $200 million in revenue in 2024[137] - The company plans to ensure the timely completion of the project for producing 1,550 tons of non-ionic CT contrast agent raw materials, which will enhance existing production capacity and introduce new products[116] - The company is focused on advancing the registration and certification of key products, including iodinated contrast agents and MRI contrast agents, in 2025[115] - The company plans to enhance its marketing strategy, increasing the budget by 20% to drive user engagement and brand awareness[191]